New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
06:38 EDTONCYOncolytics Biotech reports 2013 EPS (28c), consensus (31c)
News For ONCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
06:34 EDTONCYOncolytics Biotech receives ODD from FDA for Reolysin
Oncolytics Biotech announced that the FDA has granted Orphan Drug Designation, or ODD, for its lead product candidate, Reolysin, for the treatment of primary peritoneal cancers. The designation was granted on the basis of the Company's December 2014 application for an Orphan Drug Designation encompassing ovarian, fallopian tube and primary peritoneal cancers which are generally treated as one indication. On February 11, the company announced that it had received Orphan Drug Designation for ovarian cancer and for cancers of the fallopian tube on March 2.
06:32 EDTONCYOncolytics Biotech receives Orphan Drug Designation for Reolisyn
Oncolytics Biotech announced that the FDA has granted Orphan Drug Designation for its lead product candidate, Reolisyn, for the treatment of primary peritoneal cancers. The designation was granted on the basis of the Company's December 2014 application for an Orphan Drug Designation encompassing ovarian, fallopian tube and primary peritoneal cancers which are generally treated as one indication.
March 2, 2015
06:38 EDTONCYOncolytics Biotech announces receipt of Orphan Drug Designatoin for REOLYSIN
Subscribe for More Information
06:37 EDTONCYOncolytics Biotech receives ODD from FDA for Reolysin
Subscribe for More Information
February 18, 2015
06:41 EDTONCYOncolytics Biotech completes enrollment of randomized Phase II study of REOLYSIN
Subscribe for More Information
06:37 EDTONCYOncolytics Biotech completes enrollment in Phase II colorectal cancer study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use